Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric L Simpson

Showing results (241-250 of 315) with videos related to

Pageof 32
Sort By:
Journal of Drugs in Dermatology : JDD|June 4, 2025
Rapid Onset of Itch Relief With Tapinarof in Two Phase 3 Trials in Atopic DermatitisEric L Simpson, Jonathan I Silverberg, Robert Bissonnette, et al.
Journal of the American Academy of Dermatology|March 6, 2020
Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOSJonathan I Silverberg, Gil Yosipovitch, Eric L Simpson, et al.
The Journal of Pediatrics|May 1, 2022
The Family Impact of Atopic Dermatitis in the Pediatric Population: Results from an International Cross-sectional StudySebastien Barbarot, Jonathan I Silverberg, Abhijit Gadkari, et al.
The Journal of Allergy and Clinical Immunology|March 30, 2022
The HOME Core outcome set for clinical trials of atopic dermatitisHywel C Williams, Jochen Schmitt, Kim S Thomas, et al.
The Journal of Investigative Dermatology|December 12, 2018
A Phase 2 Randomized Trial of Apremilast in Patients with Atopic DermatitisEric L Simpson, Shinichi Imafuku, Yves Poulin, et al.
Trials|March 6, 2020
A Community-based Assessment of Skin Care, Allergies, and Eczema (CASCADE): an atopic dermatitis primary prevention study using emollients-protocol for a randomized controlled trialBrian Eichner, Le Ann C Michaels, Kelsey Branca, et al.
Dermatology and Therapy|June 28, 2021
Correction to: Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe ADRebecca Hall, Mark G Lebwohl, Andrew G Bushmakin, et al.
The Journal of Dermatological Treatment|June 11, 2019
Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2Michael J Cork, Laurent Eckert, Eric L Simpson, et al.
Dermatology and Therapy|December 31, 2020
Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe ADRebecca Hall, Mark G Lebwohl, Andrew G Bushmakin, et al.
Experimental Dermatology|May 18, 2021
Insights into adult atopic dermatitis heterogeneity derived from circulating biomarker profiling in patients with moderate-to-severe diseaseJonathan T Sims, Ching-Yun Chang, Richard E Higgs, et al.
Pageof 32

Showing results (241-250 of 315) with videos related to

Sort By:
Pageof 32
Journal of Drugs in Dermatology : JDD|June 4, 2025
Rapid Onset of Itch Relief With Tapinarof in Two Phase 3 Trials in Atopic DermatitisEric L Simpson, Jonathan I Silverberg, Robert Bissonnette, et al.
Journal of the American Academy of Dermatology|March 6, 2020
Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOSJonathan I Silverberg, Gil Yosipovitch, Eric L Simpson, et al.
The Journal of Pediatrics|May 1, 2022
The Family Impact of Atopic Dermatitis in the Pediatric Population: Results from an International Cross-sectional StudySebastien Barbarot, Jonathan I Silverberg, Abhijit Gadkari, et al.
The Journal of Allergy and Clinical Immunology|March 30, 2022
The HOME Core outcome set for clinical trials of atopic dermatitisHywel C Williams, Jochen Schmitt, Kim S Thomas, et al.
The Journal of Investigative Dermatology|December 12, 2018
A Phase 2 Randomized Trial of Apremilast in Patients with Atopic DermatitisEric L Simpson, Shinichi Imafuku, Yves Poulin, et al.
Trials|March 6, 2020
A Community-based Assessment of Skin Care, Allergies, and Eczema (CASCADE): an atopic dermatitis primary prevention study using emollients-protocol for a randomized controlled trialBrian Eichner, Le Ann C Michaels, Kelsey Branca, et al.
Dermatology and Therapy|June 28, 2021
Correction to: Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe ADRebecca Hall, Mark G Lebwohl, Andrew G Bushmakin, et al.
The Journal of Dermatological Treatment|June 11, 2019
Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2Michael J Cork, Laurent Eckert, Eric L Simpson, et al.
Dermatology and Therapy|December 31, 2020
Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe ADRebecca Hall, Mark G Lebwohl, Andrew G Bushmakin, et al.
Experimental Dermatology|May 18, 2021
Insights into adult atopic dermatitis heterogeneity derived from circulating biomarker profiling in patients with moderate-to-severe diseaseJonathan T Sims, Ching-Yun Chang, Richard E Higgs, et al.
Pageof 32